 Home > Active Ingredient News > Drugs Articles > Straight to JPM: Gilead was protested on the spot because of the price increase; Pfizer Global CEO Responds to P Drug Strategy in China; Johnson & Johnson, BMS have huge acquisitions...

Straight to JPM: Gilead was protested on the spot because of the price increase; Pfizer Global CEO Responds to P Drug Strategy in China; Johnson & Johnson, BMS have huge acquisitions...

 Last Update: 2023-02-01
 Source: Internet
 Author: User

Tags

autoimmune ear disease

face care products

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

New industry interests, focused on driving integration and services
.

In 2023, we will see more M&A deals
.

Biopharmaceutical companies may have fewer opportunities to invest
.

On January 9, 2023, local time, the 41st J.
P.
Morgan Annual Meeting (J.
P.
Morgan Healthcare) was held for four days.
Morgan Healthcare Conference, JPM), kicked off at The Westin St.
Francis San Francisco
.

The conference invited global investors and thought leaders, including industry, market, academia and government, with a total of about 8,000 participants
.
In terms of pharmaceutical companies, from pharmaceutical companies that are among the top 100 companies in the world to biotech companies from all over the world, the conference welcomed more than 550 companies
.
Among them, there are many Chinese new drug R&D companies
such as BeiGene, Hengrui, Rongchang, Innovent and Ascentage.

Shortly after the JPM conference three years ago, the world pressed the pause button
.
Affected by the epidemic, many guests have been separated from the JPM conference for three years
.
"In the past three years, so much has changed
.
" One of the guests sighed
.

"In 2022, the global pharmaceutical and biotech industry is generally experiencing a challenging financing environment, as well as complex geopolitical issues, and the cost of capital continues to rise
.
" Michael, head of global healthcare at JPMorgan Speaking at the opening ceremony, Gaito said, "This funding environment is very challenging
.
Although some funding restrictions have been relaxed since the end of the year, this year's cash flow may still be not optimistic
.
”

Michael, head of global healthcare at JPMorgan Speaking at the opening ceremony, Gaito said, "This funding environment is very challenging
.
Although some funding restrictions have been relaxed since the end of the year, this year's cash flow may still be not optimistic
.
”

Pessimistic, Gaito added: "Despite the difficult funding environment, we are pleased to see a lot of incredible innovation
in areas of diseases such as diabetes and Alzheimer's.
”

In line with Gaito's speech, attendees also exhibited mixed emotions
.
"As the pandemic calms down and the number of companies that need immediate financing increases, biopharmaceutical companies may have fewer opportunities to invest
.
" One panelist said
.

While anxious about the looming global recession, panelists were also excited
about new investments and M&A deals for next-generation treatments.

"Many expect to see more M&A deals in 2023, with more and more acquisitions by multinational pharmaceutical companies of smaller biotech companies
.
" He added
.

"New industry interests are focused on driving consolidation and services
.
" Gaito thinks
.
"Not long ago, Amgen was on Horizon Therapeutics' merger is a good example
.
Another investor said, "Italian pharmaceutical company Chiesi Farmaceutici also announced the acquisition of Amryt on Monday Pharma
。 ”

It is worth noting that Summit Therapeutics, which has just announced a cooperation with Akeso, also appeared at the JPM conference and highlighted this cooperation and subsequent plans
.

01 Pfizer: "Better days are yet to come"

Recently, Pfizer, which was put on the cusp of Chinese public opinion due to the negotiation of the new crown drug Paxlovid, explained Paxlovid's next plan
in China at the JPM conference.

Pfizer CEO Albert Bourla said it has no plans to open generic Paxlovid licenses to China, but has reached agreements with Chinese partners to localize Paxlovid production for the Chinese market
.

For Pfizer, although it is difficult to continue the surge in performance based on new crown-related products in the future, this does not mean that Pfizer will enter a dangerous place
.
Albert Bourla predicts that vaccination rates will decline or stabilize above 30 percent next, and Albert Bourla expects the coming wave of outbreaks to be more severe and treatment rates to rise
.

In addition, Pfizer also said at the R&D conference held on December 12, 2022, even after its COVID franchise from 2022 It is expected to flatten after the decline in annual sales peaks, but it is believed that the franchise will remain a multibillion-dollar source of revenue for the foreseeable future
.

"Pfizer had the most successful year
in its history.
" Albert Bourla thinks
.

Albert Bourla was quite optimistic about the future at the JPM meeting, "I fully believe that the best days are yet to come," Albert said Bourla disclosed that Pfizer will launch 19 products in the next 18 months and expects non-COVID revenue to reach $84 billion
in 2030.

Among its products, an important research and development direction is gene therapy
.
At the 2022 JPM conference, Pfizer said that it would go all out to make more gene cell therapy deals, hoping to become a leader in the field and maintain a compound annual growth rate
of 6% by 2030.
At the research and development conference on December 12, 2022, Pfizer introduced the progress of new drugs and said that it once again said that the company's enthusiasm for gene therapy has not changed and is full of confidence
in the future of gene therapy.

02 Johnson & Johnson: Aiming for $60 billion in pharmaceutical sales in 2025

02 Johnson & Johnson: Aiming for $2025 billion in pharmaceutical sales in 600

The medical giant Johnson & Johnson, which is in the period of integration, is still the focus
of attention at the conference.

It is understood that Johnson & Johnson plans to spin off the consumer health business in 2023 to focus on the pharmaceutical and medical device businesses
.
Johnson & Johnson has recently submitted plans
to spin off its consumer health business.
According to its filing with the U.
S.
Securities and Exchange Commission (SEC) The documents say the spin-off company, called Kenvue, will include Johnson & Johnson brands
such as Tylenol, Listerlin, Neutrogena and Nicorette.

Wall Street analysts predict that after divesting the consumer health sector, Johnson & Johnson may strengthen the medical business
through acquisitions.
Johnson & Johnson has already begun to act, and in late 2022, Johnson & Johnson announced the acquisition of all outstanding shares
of artificial heart maker Abiomed for $11.
6 billion.
It is understood that this acquisition is the first large-scale acquisition since Johnson & Johnson announced the divestment of its consumer health business, and it is also one of
the largest acquisitions in Johnson & Johnson's history.

As for the planned acquisition, CEO Joaquin Duato again explicitly denied Horizon at the JPM conference Pharma is interested in acquisitions and said Johnson & Johnson has the ability to identify and onboard outside development channel opportunities, but did not disclose more specifics about
the company's acquisition.
Joaquin Duato expects Johnson & Johnson to continue to grow toward its $60 billion pharmaceutical sales target by 2025 and is confident it will exceed current Wall Street expectations
in the target year.

Its CEO, Joaquin Duato, again explicitly denied Horizon at the JPM conference Pharma is interested in acquisitions and said Johnson & Johnson has the ability to identify and onboard outside development channel opportunities, but did not disclose more specifics about the company's acquisition

03 Novartis: Focus on five major therapeutic areas and the US market

Novartis' JPM visit re-emphasized its 2023 strategy's focus on five core therapeutic areas and its important goal
of improving its U.
S.
market position with an "America First" approach.

The five therapeutic areas are cardiovascular, immunology, neuroscience, solid tumors and hematology
.
CEO Vas Narasimhan said at the meeting that Novartis plans to promote the development of five major areas through the gene therapy portfolio, and more than 15 projects are continuing to advance
.
And revealed that with its new generation platform T-Charge, most of the efforts are focused on the cell and gene therapy track, and is trying to advance CAR-T therapy
for patients with advanced systemic lupus erythematosus (SLE) and other serious immune diseases.

It is reported that Novartis' T-Charge platform can make CAR-T cell expansion mainly occur in patients, without the need to extend the culture time
in vitro.
Compared with traditional CAR-T, the T-Charge platform only takes less than 2 days to complete the production of CAR-T cells, and retains the ability of
T cells to self-renew and mature.

As early as April 2022, Novartis formulated a new global strategy, launched a new organizational structure and operating model, laid off 8,000 employees, positioned innovative drugs and digitalization as the focus of its transformation layout, and spun off its generic drug division Sandoz
in the same year.

While developing new drugs in five areas, Narasimhan said that although Novartis is Europe's "number one player," one of its main goals this year is to improve its position
in the U.
S.
market with an "America First" approach.
To increase its presence in the U.
S.
, Novartis will increase the share of U.
S.
patients in clinical trials and deploy talent
in the country.

Last September, Novartis said at an investor event that Novartis aims to become the top five drugmakers
in the U.
S.
by 2027.

The strategic goal is supported by 8 potential blockbuster products (Cosentyx, Entresto, Gilenya, Zolgensma, etc.
) that Novartis believes have the potential
to peak in multibillion-dollar sales.
In the third quarter of last year, Novartis Innovative Drugs' revenue was US$10.
299 billion, down 3% year-on-year; Generic drug revenue was $2.
244 billion, down 7%
year-over-year.
The company's TO3 sales are the autoimmune drug Cosentyx, the heart failure drug Entresto and the multiple sclerosis drug Gilenya, which are also the most critical drugs driving Novartis' growth, in addition to the strong growth of its oncology drug Kisqali and multiple sclerosis drug Kesimpta
.

04 BMS: Continue to diversify

At JPM 2022, BMS's message focused on striving to grow against the patent cliff, announcing that it would ramp up its internal and external innovation pipeline
with approximately $50 billion in cash flow between 2022 and 2024.

At this year's JPM conference, Chris Boerner, Executive Vice President and Chief Commercial Officer of BMS, continued to explain the company's important steps
to overcome the patent cliff.

The data shows that BMS Revenue for the third quarter of 2022 was US$11.
218 billion, down 3%
year-over-year.
Affected by the expiration of the patent, Revlimid (lenalidomide) and Abraxane (albumin paclitaxel) became BMS The main reason for
the negative growth in Q3.

Its performance growth was mainly driven by the anticoagulant Eliquis, O drugs, and the immunomodulatory drug Pomalyst/Imnovid
.
According to the Vantage Preview Report 2023" predicts that BMS's once top sales Revlimid will fall out of the world's top ten best-selling drugs, and Revlimid will also rank the world's second best-selling oncology drug
with sales of $12.
8 billion in 2021 after K drugs.
Its O drug will rise 3 places in 2023 to 6th in the
world's best-selling drug.

BMS is launching a younger and more diversified portfolio, with 9 new drugs
launched between 2020 and 2022.
Only in 2022 This year, BMS has 3 new drugs approved by the FDA, including the melanoma drug Opdualag (nivolumab+ relatlimab), hypertrophic cardiomyopathy drug Camzyos (mavacamten) and psoriasis drug Sotyktu (deuterium colexitinib).

BMS says diversification is key
to its next phase of growth.
In the future, the 6 major product candidates of milvexian, iberdomide, mezigdomide, BMS-986278, repotrectinib and cendakimab will be the main growth drivers
in its future.
In addition, BMS estimates that from the $74 billion acquisition of Celgene in 2019 to 2030, about 50% of revenue will come from acquisitions
.

BMS says diversification is key to its next phase of growth

05 Eli Lilly: Promote the listing of five major drugs

For the new year, Lilly has to be busy
.

"We are now busy driving the development and launch
of five major products.
"

On the first day of JPM, before the sun had risen, Lilly's two executives were already busy, calling 2023 the year Big Pharma embraced new models and new drugs
.

"This is an exciting time," said Patrik, president and executive vice president, president of immunology and chief customer officer of Eli Lilly America Jonsson revealed his expected release and a new wave of
innovations.

Eli Lilly's top five drugs currently driving performance growth are dulaglutide, eccilizumab, abecilide, empagliflozin and baricitinib
.
In addition, a number of drugs in clinical phase III have attracted much attention
.

Not long ago, after the FDA accelerated the approval of Eisai and Biogen's joint development of the drug lecanemab for the treatment of Alzheimer's disease, Lilly's Donanemab became the next target
of attention.
Daniel, Senior Vice President, Chief Scientific and Medical Officer and President of Eli Lilly Research Laboratories Skovronsky told the Morgan conference that Lecanemab's approval is a win-win and not only beneficial to the field, but also to Alzheimer's patients
.

On November 30, 2022, Eli Lilly announced the results of the Aduhelm head-to-head trial with Biogen/Eisai, in which the Donanemab Phase III study for the treatment of early Alzheimer's disease (AD) met all primary and secondary endpoints in a 6-month analysis, has now completed a rolling marketing application for the product, and the FDA expects to make a decision on approval in February 2023
.
Daniel Skovronsky said,

If the lecanemab test fails, it could mean that Donanemab may be less effective, as both monoclonal antibodies are based on amyloid clearance
.

In addition, in 2023, Eli Lilly plans to launch the immunological drug mirikizumab for ulcerative colitis and lebrikizumab for atopic dermatitis, both of which are currently under FDA review
.
Jonsson said Eli Lilly expects to launch mirikizumab in the United States, Europe and Japan in the first half of this year.
Lebrikizumab is scheduled to launch
by the end of 2023.

Eli Lilly also revealed that its small molecule next-generation BTK inhibitor, pirtobrutinib, will enter the market for patients
with relapsed/refractory mantle cell lymphoma who have previously been treated with BTKi.
Finally, there is its GLP-1/GIP dual-target drug tisiparatide, which is currently undergoing Phase 3 evaluation, after beating semeglutide
in a head-to-head clinical trial.

06 Gilead: Not very eager for big mergers and acquisitions

Unlike other pharmaceutical companies, Gilead's JPM conference tour, the most talked about thing, took place off-site
.
In front of the event venue, where many pharmaceutical giants fented, a protest against Gilead took place
.

Protesters at the AIDS Health Care Foundation (AHF) criticized Gilead for doubling the price of his acquired immunodeficiency syndrome (AIDS) treatment and continued to protest
around the venue holding up signs such as "Stop greed" and "Gilead cares more about money than life.
"

AHF has publicly protested Gilead several times to express its dissatisfaction with the price increase, and Gilead's HIV drug price has repeatedly caused controversy
.
As early as 2019, Gilead raised the price of 14 products, of which the price of HIV therapy Genvoya, Truvada, Odefsey, Descovy and other drugs was increased by 4.
9%.

Earlier, the AHF led grassroots marches in Washington, Miami, and San Diego to protest Gilead's voracious drug pricing policies
, particularly on HIV and hepatitis C drugs.

AHF has publicly protested Gilead several times to express its dissatisfaction with the price increase, and Gilead's HIV drug price has repeatedly caused controversy
.

In 2022, an HIV-positive consumer joined a federal lawsuit against Gilead, accusing the company of unfair anti-competitive practices by bribing competitors to prevent generic versions of the HIV drug Truvada from entering the market
.

According to the third quarter of 2022 financial report, Gilead has nearly 10 HIV drugs, of which Biktarvy is among the top ten "bombshells" in the pharmaceutical industry in 2022 previously counted by E drug managers
.

Combined with the first three quarters of 2022 financial reports, BMS's Alto and Gilead's Bitova followed K with sales of US$9.
072 billion and US$7.
507 billion, respectively
.
It has focused on growing its oncology portfolio and maximizing its HIV drug franchise
.

The company's long-term HIV treatment Sunlenca recently received FDA approval for severely treated patients and is testing its effectiveness
as a treatment and prevention tool in various studies.
Gilead previously said the wholesale acquisition cost (WAC) for Sunlenca injections and tablets is expected to be $42,250 in the first year of treatment and $39,000 for maintenance annually
.

Meanwhile, Gilead Chief Financial Officer Andrew Dickenson told JPM that there's still a lot to do and a lot to digest
.
He also said that Gilead is not very eager for large mergers and acquisitions in 2023, but that does not mean that no deals
will be made this year.
However, even if there is a deal move, it may not be comparable to the large deals that have been reached before
.
For example, in 2020, it acquired Immunomedics for US$21 billion to fill the investment direction of oncology drugs other than hepatitis B, hepatitis C, HIV and other antiviral drugs to drive performance growth
.

07 Moderna: "Significantly increased investment in R&D"

Stephane, CEO of Moderna Bancel said at the meeting that Moderna's full-year 2022 sales totaled $18.
4 billion, down from a previous forecast of $21 billion
.
Bancel also promised that Moderna will be "in a better position"
in 2023.

For 2023, Bancel said that the sales of new crown vaccines that the industry is more concerned about are at least linked
to the confirmed pre-purchase agreement and the continuation of the 2022 contract.

According to the JPM conference, Moderna's new crown vaccine may cost between
$110 and $130 per dose when it goes on sale this year.
By contrast, the U.
S.
federal government pays well below the potential new price
for each shot of the Moderna vaccine.
Under a federal contract signed over the summer, it's about $
26 per dose.

Bancel said, "This pricing is consistent with
value.
”

While U.
S.
adoption of bivalent boosters has been slow, with just over 15 percent of people ages 5 and older receiving the newer vaccine, Moderna's chief commercial officer, Arpa Garay also predicted on his latest quarterly conference call that the coronavirus vaccine market will be "as big or bigger as the flu market.
"

It is understood that due to the US federal government's vaccine purchase program, the new crown vaccine is currently available
to everyone free of charge.
However, once the US declares an end to the coronavirus public health emergency, this is expected to end
as well.

Beyond vaccines, Bancel said Moderna is currently developing five latent virus vaccines, each representing a multibillion-dollar market opportunity
.
In the broader use of respiratory diseases, Bancel said its phase III RSV study has met the number of cases needed for the first efficacy analysis, and flu data may be released
this quarter.
Moderna also hopes to launch a Phase III trial
of its mRNA-based cancer vaccine in combination with Merck's Melanoma Keytruda this year.

Commenting on this series of actions, Bancel said in a press release: "The board has approved a significant increase in R&D investment, with a budget of approximately $4.
5 billion for 2023," Bancel said in a press release,"

08 Bluebird Creature: Burn another 300 million this year

08 Bluebird Creature: Burn another 3 million this year

Until the FDA-approved gene therapy last year, Bluebird Bio's future looks uncertain
.
Heading into 2023, gene therapy seems to be gaining a
foothold.

At the JBM conference, Bluebird said it has treated its first commercial patient
with Zynteglo, the β thalassemia gene therapy.
The company said it sees "significant patient demand" for the newly approved therapies and expects to sell the product
for the first time in the first quarter of this year.

Bluebird Bio's Zynteglo received FDA approval last August for treating thalassemia patients
who require regular red blood cell transfusions β.
As a disposable gene therapy, the drug costs millions of dollars
.
To support the actual results of medicine, Bluebird is offering outcome-based pricing
to payers.

In that regard, Bluebird said the three major pharmacy benefit managers in the U.
S.
have signed outcome-based treatment agreements
.
The company said the lives of 190 million patients in the U.
S.
are protected
by the drug's "favorable" policy.

Bluebird, meanwhile, has launched 10 gene therapy centers and is in the process of joining another 15
.
By the end of the year, the company expects to have 40 to 50 treatment centers
in its U.
S.
network.

As for Skysona, the company's cerebral adrenal leukodystrophy (CALD) gene therapy, Bluebird said cell collection from the first patient is scheduled for this month
.
The drug received FDA approval last September for $3 million
.

As the product goes to market, Bluebird expects to burn $270 million to $300 million in cash
this year.
As the company recently netted nearly $200 million from the sale of priority review vouchers, plus other assets on hand, Bluebird believes it can operate until at least the first quarter
of 2024.

09 Summit: "Ivonescimab has become a core asset"

On December 6, 2022, Summit Therapeutics, which has just announced a cooperation with Akeso, also appeared at the JPM conference
.

At the end of 2022, Summit introduced Akeso's PD-1/VEGF dual antibody in hopes of developing it into a blockbuster product
.
At the JPM Annual Meeting, Summit highlighted this collaboration and its follow-up plans
.

Summit said that Yu Xia, the founder of Akeso, has joined Summit's board of directors, and Ivonescimab (PD-1/VEGF bispecific antibody) has become Summit's core asset
.
Summit plans to initiate Phase III clinical
trials of Ivonescimab in 2023-2024, either alone or in collaboration with Akeso.

It is reported that Ivonescimab has obtained breakthrough therapy certification for three indications in China, including non-small cell lung cancer in the backline of EGFR-TKI, combination chemotherapy for PD-(L)1-resistant non-small cell lung cancer, and first-line treatment for PD-L1-positive advanced non-small cell lung cancer
.

According to data from ASCO2022, Ivonescimab monotherapy has a good safety profile, with a 13.
5% incidence of grade 3-4 side effects, and no side effect discontinuation events
.
First-line therapy, doses above 20 mg/kg, for TPS The ORR was 50% in 1-49% of patients and 76.
9% in 50% of patients with TPS≥ and 50%.

Summit said it is about to make a $500 million rights issue to cover Akeso's advance ($475 million in cash and $25 million in equity in 10 million shares), leaving $174 million in cash available through mid-2024
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.